Adenocarcinoma of the small intestine
ORPHA:104075DiseaseNot applicableAdult
Эпидемиология25
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.588 | Europe | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.517 | Austria | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.734 | Belgium | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.174 | Bulgaria | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.308 | Croatia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.464 | Czech Republic | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.36 | Estonia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.574 | Finland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.657 | France | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.551 | Germany | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.724 | Iceland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.564 | Ireland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.79 | Italy | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.265 | Latvia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.277 | Lithuania | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.377 | Malta | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.788 | Norway | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.219 | Poland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.743 | Portugal | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.462 | Slovakia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.4 | Slovenia | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.477 | Spain | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.76 | Switzerland | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.626 | Netherlands | Value and class |
| Annual incidence | 1-9 / 1 000 000 | 0.679 | United Kingdom | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)